OB

Oxford Biomedica

Organization

Heard in 3 episodes across 2 shows since Aug 2026

Oxford Biomedica (OXB) is a leading gene and cell therapy company specializing in the development and manufacturing of gene-based medicines. Operating as a contract development and manufacturing organization (CDMO), it provides critical viral vector solutions to power progressive cell and gene therapies globally.

Episodes

3
across 2 shows

First heard

Aug 2026

Expert statements

6
6 negative

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20263
Sep 20260
Oct 20260
Nov 20260

Email alert

Email me when Oxford Biomedica comes up on a podcast

One email a week at most, with the new episodes that mention Oxford Biomedica. Free, no account needed, unsubscribe in one click.

What experts have said about Oxford Biomedica

6 statements · 6 negative

  1. Louise MoonNegativeAug 18, 2026· Stock Movers

    Oxford Biomedica cut its full-year revenue and profitability guidance.

    “they cut their full year revenue and profitability guidance.”

    Listen at 4:05

    Open the episode · Frasers Group Up, Royal Unibrew Drops, OXB Down
  2. Oxford Biomedica remains loss-making and cash-burning, making valuation difficult.

    “it doesn't make any money. It's loss-making and cash-burning, so it's quite a leap of faith here to actually value it.”

    Listen at 14:58

    Open the episode · Paul's Podcast - Fri 7 Aug 2026
  3. Oxford Biomedica is loss-making and consuming cash, complicating valuation.

    “It's loss-making and cash-burning, so it's quite a leap of faith here to actually value it.”

    Listen at 14:59

    Open the episode · Paul's Podcast - Fri 7 Aug 2026

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

3 episodes featuring Oxford Biomedica, newest first